StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

Stock analysts at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 16.3 %

Shares of CPIX stock opened at $4.47 on Thursday. Cumberland Pharmaceuticals has a fifty-two week low of $1.04 and a fifty-two week high of $6.43. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The business has a fifty day simple moving average of $2.42 and a 200-day simple moving average of $1.68. The stock has a market cap of $62.76 million, a P/E ratio of -5.81 and a beta of 0.12.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. The business had revenue of $9.09 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.